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Abstract: Autoimmune myositis encompasses various myositis-over-
lap syndromes, each being identified by the presence of serum marker
autoantibodies. We describe a novel myositis-overlap syndrome in 4
patients characterized by the presence of a unique immunologic marker,
autoantibodies to nuclear pore complexes. The clinical phenotype was
characterized by prominent myositis in association with erosive, anti-
CCP, and rheumatoid factor-positive arthritis, trigeminal neuralgia,
mild interstitial lung disease, Raynaud phenomenon, and weight loss.
The myositis was typically chronic, relapsing, and refractory to corti-
costeroids alone, but remitted with the addition of a second immuno-
modulating drug. There was no clinical or laboratory evidence for liver
disease. The prognosis was good with 100% long-term survival (mean
follow-up 19.5 yr).
By indirect immunofluorescence on HEp-2 cells, sera from all
4 patients displayed a high titer of antinuclear autoantibodies (ANA)D, FRCPC, Fran MSc, FRCPC,
arie-Christine Dabauvalle, PhD
microscopy. In a cohort of 100 French Canadian patients with auto-
immunemyositis, the nuclear pore complex fluorescent ANA pattern was
restricted to these 4 patients (4%). It was not observed in sera from 393
adult patients with systemic sclerosis (n¼ 112), mixed connective tissue
disease (n¼ 35), systemic lupus (n¼ 94), rheumatoid arthritis (n¼ 45), or
other rheumatic diseases (n¼ 107), nor was it observed in 62 normal
adults.
Autoantibodies to nuclear pore complexeswere predominantly of IgG
isotype. No other IgG autoantibodymarkers for defined connective tissue
diseases or overlap syndromes were present, indicating a selective and
highly focused immune response. In 3 patients, anti-nuclear pore complex
autoantibody titers varied in parallel with myositis activity, suggesting a
pathogenic link to pathophysiology. The nuclear pore complex proteins,
that is, nucleoporins (nup), recognized by these sera were heterogeneous
and included Nup358/RanBP2 (n¼ 2 patients), Nup90 (n¼ 1), Nup62
(n¼ 1), and gp210 (n¼ 1). Taken together the data suggest that nup
autoantigens themselves drive the anti-nup autoimmune response. Immu-
nogenetically, the 4 patients shared the DQA10501 allele associated
with an increased risk for autoimmune myositis.
In conclusion, we report an apparent novel subset of autoimmune
myositis in our population of French Canadian patients with connective
tissue diseases. This syndrome is recognized by the presence of a unique
immunologicmarker, autoantibodies to nuclear pore complexes that react
with nups, consistent with an ‘‘anti-nup syndrome.’’
(Medicine 2014;93: 383–394)
Abbreviations: ACR = American College of Rheumatology, AIM =
autoimmune myositis, ALBIA = addressable laser bead
immunoassay, ANAs = autoantibodies to nuclear antigens, CENP-
B = centromere protein B, CK = creatine kinase, CHUM = Centre
Hospitalier de l’Universite´ de Montre´al, DLCO = carbon monoxide
lung diffusing capacity, ELISA = enzyme-linked immunosorbent
assay, ENMC = European Neuromuscular Centre, LC-1 = liver
cytosolic-1 antigen, LIA = line immunoassay, LKM-1 = liver-kidney-
microsome-1, MCTD = mixed connective tissue disease, MDA-5 =
melanoma differentiation-associated protein 5, MTX = methotrexate,
NPCs = nuclear pore complexes, NUPs = nucleoporins, OM =
overlap myositis, PBC = primary biliary cirrhosis, PML =
promyelocytic leukemia cell antigen, SLA/LP = soluble liver
antigen/liver pancreas antigen, SLE = systemic lupus
erythematosus, RNP = ribonucleoprotein, SRP = signal recognition
particle, SumoAE = small ubiquitin-like modifier activating enzyme,
TRIM21 = tripartite motif.TRODUCTION
uclear antigens (ANAs) are important
ognostic markers in the autoimmune
www.md-journal.com | 383
connective tissue diseases.23,50,52 ANAs are routinely detected
by indirect immunofluorescence on cultured human cells such
as HEp-2 cells. Fluorescent patterns as detected on ANA
substrates provide clues to the antigenic specificity of ANAs
and to the presumptive molecular identity of cognate autoanti-
gens. Typical examples are the speckled fluorescent ANA
pattern associated with anti-U1RNP in mixed connective tissue
disease (MCTD) and the centromere fluorescent ANA pattern,
which suggests the presence of anti-CENP-B autoantibodies
associated with the limited cutaneous subset of systemic
sclerosis.23,50,52
Nuclear envelope acquisition is a landmark event in the
evolution of eukaryotic cells. By encasing the genome, this
distinct double lipid membrane forms a physical barrier facing
externally the cytoplasm and the endoplasmic reticulum lumen
and, internally, the nuclear chromatin.18,44 The transport of
macromolecules between the nucleus and the cytoplasm is
mediated through nuclear pore complexes (NPCs), which
generate a highly selective and dynamic permeability bar-
rier.14,18a,20 Each NPC has a core structure consisting of a
hollow cylinder embedded in the nuclear envelope and is
composed of about 30 different proteins termed nucleoporins
(nups).14,18a,20,28 The NPC structure contains 3 major domains:
the central framework consisting of the selective central chan-
nel, or central transporter region, the cytoplasmic ring com-
posed of a protein complex and cytoplasmic filaments, and the
nuclear ring with nucleus extending filaments forming a basket-
like structure. The different nups are distributed in 1 of these
3 NPC domains. Nups can be divided in 2 main classes. The first
class of nups represents a stable scaffold involved in stabiliz-
ation and maintenance of the pore membrane, whereas the
second class includes peripheral and mobile nups responsible
for transport functions. In addition to their transport roles, nups
have critical roles in chromatin organization, mitosis, DNA
repair and regulation of gene expression.14,18a,20,28 Given the
critical roles of the NPC in cellular functions, it is not surprising
that a growing number of reports reveal the involvement of nups
in specific human diseases.6,44
In 1988, our team described an autoantibody to NPCs (anti-
NPC) in serum from patient LGL with autoimmune myositis
(AIM) and trigeminal neuralgia.10 This autoantibody was
associated with a characteristic punctate peripheral (rim) fluor-
escent nuclear pattern on HEp-2 cells and was shown by
immunogold electron microscopy to react with NPCs on the
cytoplasmic side of the nuclear envelope.10 Anti-NPC persisted
in serial serum samples over 2 years and appeared to fluctuate in
parallel with myositis activity.
Subsequently, a small number of anti-NPC autoantibodies
were found to be associated with organ-specific autoimmune
diseases.11 As an example, autoantibodies to the nups gp210 and
p62 were associated with primary biliary cirrhosis (PBC),
occurring in 25% of patients.11,55 However, no study has
reported thus far on the frequency of anti-NPC in a large
population of patients with connective tissue diseases.
Since the original description of anti-NPC in patient LGL,
we have identified in a cohort of French Canadian patients with
connective tissue diseases 3 additional patients with a charac-
teristic anti-NPC fluorescent ANA pattern. As in the case of
patient LGL, these patients were referred for evaluation of a
connective tissue disease. We present herein the clinical and
serologic course of these 4 patients over prolonged follow-up.
Sene´cal et alThese patients share a peculiar overlap connective tissue syn-
drome and clinical phenotype characterized by prominent
myositis. This syndrome is associated with a good overall
384 | www.md-journal.comprognosis and prolonged survival. Immunologically, anti-
NPC were of IgG isotype that targeted several nup autoantigens
and were not associated with other major autoantibody markers.
Moreover, anti-NPC titers fluctuated in parallel with myositis
activity, suggesting a relationship to pathogenesis.
PATIENTS AND METHODS
Patients and Controls
The 4 index patients with anti-NPC were from a cohort of
adult French Canadian patients with connective tissue diseases
evaluated and followed longitudinally between 1984 and 2001
by our team at the Connective Tissue Diseases Clinic, Division
of Rheumatology, Centre Hospitalier de l’Universite´ de Mon-
tre´al (CHUM), as described.24,37,41,50 Patients recruited in this
cohort are classified as systemic sclerosis or systemic lupus
erythematosus (SLE) according to American College of Rheu-
matology (ACR) disease criteria. Patients with AIM were
classified as overlap myositis, polymyositis, dermatomyositis
and cancer-associated myositis, as described.50 Definitions for
monophasic versus chronic myositis, myositis relapse and
refractory myositis were as reported by Troyanov et al.50 Con-
trol sera were from normal adults, and from patients with
rheumatoid arthritis (defined according to ACR criteria),
MCTD,52 autoimmune hepatitis, psoriatic arthritis, ankylosing
spondylitis, primary gout or primary osteoarthritis, as
described.41 Patients provided informed written consent for
clinical data and serum collection. Biobank and clinical data-
bank procedures were approved by the CHUM Ethical
Review Board.
Identification of Anti-NPC Autoantibodies
In all index and control patients, serum samples obtained at
the time of diagnosis and at follow-up were coded and studied
blindly by 1 of us (JLS) at the screening dilution of 1:40 for the
presence of ANAs by indirect immunofluorescence on HEp-2
cells (Antibodies Inc., Davis, CA), as described.38–40 The
presence of autoantibodies to NPCs was identified by the
characteristic punctate peripheral (rim) nuclear fluorescent
pattern.10,11 Anti-NPC pattern on HEp-2 cells is readily dis-
tinguished from the linear continuous peripheral ANA pattern
associated with anti-lamin B1 autoantibodies, and from the
broad peripheral pattern associated with anti-DNA antibodies.40
Specific NPC localization of cognate autoantigens recognized
by anti-NPC was further demonstrated by immunogold
electron microscopy on nuclear envelopes and reported else-
where.9,27,40,53,54
Variation of anti-NPC over time was studied by indirect
immunofluorescence on coded serum samples obtained at
follow-up visits and biobanked at 808C. Fluorescence inten-
sity of the NPC pattern on a scale of 0 to 4 at the screening serum
dilution (1:40) on HEp-2 cells was rated blindly by a single
observer, in single experiments for each patient. The fluor-
escence intensity at the screening dilution was used as a
surrogate for end-point titers. This was correlated with serum
creatine kinase levels (CK) measured on simultaneous serum
samples, as an indicator of muscle necrosis.4
Isotypic analysis for IgG, IgM, and IgA anti-NPC was
performed by indirect immunofluorescence on HEp-2 cells
Medicine  Volume 93, Number 24, November 2014(Antibodies Inc.) using FITC-conjugated anti-human g, m
and a heavy chain-specific antibodies (Cappel Laboratories,
Cochranville, PA).
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Line Immunoassay (LIA) and Addressable Laser
Bead Immunoassay (ALBIA)
These methods were performed by 1 of us (MJF) as
described.22 Autoantibodies against Jo-1, PL-7, PL-12, Ku-
72, Ku-86, PM-Scl, and Mi-2 autoantigens were assayed by
line immunoassay (LIA) (Euroline-WB assay, Euroimmun AG,
Luebeck, Germany). Anti-fibrillarin reactivity was tested by
ALBIA (Quanta-Plex9, INOVA Diagnostics, Inc., San Diego,
CA) on a Luminex 100 flow fluorometer (Luminex Corp.,
Austin, TX) using purified recombinant fibrillarin protein
(Mikrogen GmbH, Neuried, Germany).22
Anti-Nup62 reactivity was tested by addressable laser bead
immunoassay (ALBIA) using recombinant human Nup62 (Dia-
rect AG, Freiberg, Germany). Autoantibodies to the M2 mito-
chondrial autoantigens AMA-M2 and M2-3E(BPO), and to
the autoantigens gp210, Sp 100, liver-kidney-microsome-1
(LKM-1), promyelocytic leukemia cell antigen (PML), liver
cytosolic-1 antigen (LC-1), soluble liver antigen/liver pancreas
antigen (SLA/LP), and Ro52/TRIM21 were tested by LIA
(Euroimmun AG) as described.43
Protein A-Assisted Immunoprecipitation
Sera were analyzed by 1 of us (INT) for autoantibodies by
protein A-assisted immunoprecipitation, both for nucleic acid
analysis (RNA silver stain) and for proteins (metabolically
labelled with 35S-methionine), along with double immunodiffu-
sion.1,45,47,50 These immunoassays detect all of the described
antisynthetases (Jo-1, PL-7, PL-12, OJ, EJ, KS, Tyr and Zo),
anti-PM-Scl, anti-SumoAE, anti-RNA polymerase III, anti-Th/
To, anti-U2RNP, anti-U3RNP, anti-U5RNP, anti-SRP, anti-Mi-
2, anti-p155/140 and anti-MJ. Nucleic acid analysis used 3-5 mg
of protein A-Sepharose, 20mL of patient serum, and unlabeled
HeLa cell extract (>106 cells). Immunoprecipitates were ana-
lyzed on 7 to 8 M urea, and 10% polyacrylamide gel electro-
phoresis with silver stain development. Protein analysis used 1
to 2 mg of protein A-Sepharose, 10–15mL of serum, and 35S-
methionine-labeled HeLa cell extract (>105 HeLa cells). Immu-
noprecipitates were analyzed by SDS-polyacrylamide gel elec-
trophoresis (between 8% and 10%). None of the 4 index patient
sera with anti-NPC had any of these autoantibodies. All 4 index
sera were also negative by immunoprecipitation-blotting for
anti-p155/140, anti-MJ, and anti-MDA5.48
Other Immunoassays
Anti-CCP antibodies were detected by ELISA (CCP3,
INOVA Diagnostics).36 Values <20 units were considered
negative, between 20 and 39 low positive, 40 to 59 moderate
positive, and 60 high positive. Autoantibodies to Ro, La, Sm,
U1RNP, topo, and Jo-1 as well as rheumatoid factor were
determined by ELISA (Calbiotech, Spring Valley, CA). Anti-
native DNA antibodies were measured by filter-binding assay.40
Anti-topoisomerase I antibodies were detected by ELISA using
native full-length topoisomerase I extracted and purified from
calf thymus (Immunovision, Springdale, AR).17 Anti-CENP-B
was tested by ELISA using recombinant full-length CENP-B.51
Anti-mitochondrial antibodies (AMA) and anti-smooth muscle
antibodies (SMA) were tested by indirect immunofluorescence
on mouse tissues (CHUM Immunology Laboratory).
Medicine  Volume 93, Number 24, November 2014Capillary Microscopy
Semiquantitative nailfold capillary microscopy was per-
formed at baseline and follow-up visits.24
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Genomic DNA was extracted from peripheral blood mono-
nuclear cells using standard methods. HLA-DR, DQ, and DP
alleles were determined by polymerase chain reaction and
sequence specific oligonucleotide probes (PCR-SSOP) geno-
typing assay by 1 of us (RG, for DQA1 alleles)35 and
HLA Tissue Typing Service, ProImmune Ltd, Oxford, United
Kingdom.
RESULTS
Identification of 4 Patients With Autoantibodies
to NPCs
As part of the routine evaluation of patients referred to the
CHUM Connective Tissue Diseases Clinic, a serum sample is
obtained, coded and studied blindly for ANAs by indirect
immunofluorescence on HEp-2 cells.38–40 In sera from 4
patients (LGL, DGP, BP, and AL), the presence of anti-NPC
autoantibodies was identified by the characteristic punctate
peripheral (rim) nuclear fluorescent pattern,10,11 as shown in
Figure 1. Immunogold electron microscopic studies published
elsewhere using serum from patients LGL, DGP, and BP have
confirmed specific NPC localization.9,10,27,53,54
Anti-NPC Are Associated Clinically With
Autoimmune Myositis
Having identified at referral the anti-NPC shared by these
patients gave us the opportunity to characterize their clinical
manifestations and long-term outcome. Table 1 shows these
features before and at myositis diagnosis and over a mean
follow-up of 19.5 years.
All 4 patients were French Canadian. There were 3 women
and 1 man, with ages at the time of referral ranging from 35
years to 70 years. In the 4 patients, the dominant clinical feature
at referral was AIM requiring immunosuppressive therapy.
According to Bohan and Peter criteria, in 3 patients (LGL,
BP, and AL) myositis could be classified as ‘‘definite poly-
myositis’’ whereas in patient DGP criteria for ‘‘possible poly-
myositis’’ were fulfilled.5 However, a more current diagnosis is
overlap myositis, as recently defined.50 As shown in Table 1,
myositis was severe in patients LGL, BP, and AL, and less
severe in patient DGP. In the former 3 patients, myositis was
characterized by symmetric and proximal weakness with
muscle strength graded 3/5 or 3.5/5 associated with elevated
serum CK levels ranging from 1765 to 4836U/L. Electromyo-
graphy showed myositic abnormalities as defined by Bohan and
Peter criteria.5 Quadriceps muscle biopsies, performed before
the recent ENMC criteria,19 were consistent with idiopathic
inflammatory myopathy as defined by Bohan and Peter.5 None
of the patients was exposed to statin therapy.
Myositis in patients LGL, BP, and AL required high daily
doses of prednisone (1mg/kg), plus methotrexate (MTX) or
azathioprine as a second immunomodulating agent to induce
remission (see Table 1). In patients LGL and BP, the myositis
was refractory, that is, initial corticosteroid therapy alone failed
to induce remission, necessitating the addition of MTX (LGL)
or azathioprine (BP).50 Given this aggressive profile of anti-
NPC associated myositis, patient ALwas treated from the outset
with both corticosteroids and MTX. In all 3 patients, the
myositis course was chronic, that is, requiring long-term corti-
Anti-Nup Syndromecosteroid treatment (daily prednisone >5mg) and second-line
therapy.50 Both patients LGL and AL experienced myositis
relapses when prednisone was discontinued, necessitating
www.md-journal.com | 385
FIGURE 1. Autoantibodies to nuclear pore complexes are associated with a punctate peripheral (rim) ANA pattern. A. Indirect
immunofluorescence on HEp-2 cells was performed using serum from patient AL at 1:40 dilution. Cells were observed by confocal
microscopy. At lower magnification (inset), a dense punctate (speckled) nuclear staining is observed with a striking accentuation at the
periphery of interphase nuclei. Confocal microscopy analysis revealed that the punctate staining was not present in the nuclear interior,
and was restricted to the nuclear envelope. At higher magnification, the dense and finely speckled nuclear envelope staining is
scre
tain
tien
Sene´cal et al Medicine  Volume 93, Number 24, November 2014reintroduction of this drug. The myositis course and therapy of
patients LGL and BP are illustrated longitudinally in Figure 2.
In the 4th patient (DGP), myositis was characterized by
grade 4/5 proximal muscle weakness, oropharyngeal dysphagia,
and mild serum aldolase and CK elevation. Remission was
induced by prednisone 20mg daily alone. No myositis relapse
occurred over follow-up. Whether this favorable course was
influenced by MTX introduced later for rheumatoid arthritis
is unknown.
Other Overlap Syndrome Features Associated
With Anti-NPC
In addition to myositis, these patients shared several
overlap syndrome features, including Raynaud phenomenon
(n¼ 3 patients) and trigeminal neuropathy (n¼ 2 patients)
(see Table 1). In patient DGP, trigeminal neuropathy preceded
myositis by 4 years, whereas in patient LGL bilateral trigeminal
neuropathy occurred during the 6 months preceding myositis. In
3 patients, weight loss (3.6–7.3 kg) preceded the diagnosis of
myositis by several weeks.
highlighted, as well as the punctate peripheral (rim) pattern. Di
within annulate lamellae, an endoplasmic reticulum subdomain con
patients revealed a similar pattern.10,27,53,54 B. Patient DGP; C, PaErosive, rheumatoid factor-positive, anti-CCP positive,
and symmetric polyarthritis consistent with rheumatoid arthritis
was present in 3 patients (BP, DGP, and AL) (see Table 1). In
386 | www.md-journal.compatient BP, rheumatoid arthritis was associated with olecranial
nodules and ulnar deviation. In 2 patients, arthritis preceded
myositis by several years, whereas in patient DGP, a cigarette
smoker, arthritis onset occurred 3 years after myositis. Inter-
stitial lung disease (n¼ 2) was mild and characterized by
discrete fibrosing alveolitis on chest radiogram and pulmonary
function tests showing a restrictive pattern for patient BP and a
DLCO of 67% for patient DGP. A single patient, DGP, devel-
oped sicca symptoms with predominant xerophthalmia.
None of these patients showed features of SLE, or skin
features of dermatomyositis or systemic sclerosis. Serial nail-
fold capillary microscopy remained normal in all patients.
Anti-NPC Overlap Syndrome May Be Associated
With a Good Overall Prognosis
Although myositis required corticosteroids and a second
immunomodulating agent for therapeutic control, myositis
eventually subsided in all patients (see Table 1). No life-
threatening systemic complication nor cancer have occurred
at prolonged follow-up, with 100% survival at last visit (mean
te cytoplasmic speckles correspond to nuclear pore complexes
ing densely packed pore complexes.20 Sera from the 3 other index
t BP; D, Patient LGL.follow-up 19.5 yr, range 12–26 yr). Taken altogether, these data
suggest that anti-NPC myositis-overlap syndrome may be
associated with a good overall prognosis. However the number
# 2014 Lippincott Williams & Wilkins
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FIGURE 2. Longitudinal study reveals that titers of autoantibodies
to nuclear pore complexes (anti-NPC) vary in parallel with myo-
sitis activity. Anti-NPC titers in consecutive and coded serum
samples obtained from 2 patients over 10 and 4 years after
myositis diagnosis, respectively, were measured by grading
NPC fluorescence intensity (FI) on a scale of 0 to 4 at the screening
dilution (1:40) on HEp-2 cells. FI was used as surrogate for titers
and plotted with synchronous serum CK levels. Top panel. Patient
LGL. The highest anti-NPC titer (FI of 3, endpoint titer 1:1280)
correlated with the highest serum CK level (at year 0), followed by
progressive fall and disappearance of anti-NPC with prednisone
andmethotrexate-induced remission (years 1 to 7). A lower titer of
anti-NPC was persistently present from years 2 to 5, and then the
autoantibody became undetectable. Immunosuppressive treat-
ment discontinuation because of remission during year 7 was
followed in late year 7 by a striking rise in anti-NPC titer and serum
CK levels, together with a clinical myositis relapse, followed in year
8 by falling anti-NPC with treatment reinstitution and improving
myositis. Bottom panel. Patient BP. The highest anti-NPC titer
(FI of 3.5, endpoint titer 1:2560) correlated with the highest
serum CK level (at year 0), followed by progressive fall of anti-
Medicine  Volume 93, Number 24, November 2014of patients reported herein is small and more patients will need
to be studied.
Anti-NPC Parallel Myositis Activity
High titers of anti-NPC, ranging from 1:1280 to 1:10,240,
were present at myositis diagnosis in sera from all 4 patients
(Table 2). Anti-NPC titers fluctuated in parallel with the serum
CK level in patients LGL, BP, and AL. This is illustrated in
NPC over 2 years and disappearance with sustained prednisone
and azathioprine-induced myositis remission (years 2 to 4).
No myositis relapse followed discontinuation of azathioprine after
5 years.Figure 2 for patients LGL and BP. For both patients, the highest
anti-NPC titer correlated with the highest CK level, followed by
a progressive fall of anti-NPC to undetectable levels with
# 2014 Lippincott Williams & Wilkinstreatment-induced remission. In patient AL, a similar decrease
in anti-NPC titer in parallel with decreasing myositis activity
was observed in consecutive serum samples over 5 months.
Interestingly, in patient LGL a striking rise of anti-NPC
coincided with clinical and enzymatic myositis relapse follow-
ing discontinuation of prednisone and MTX because of remis-
sion (Figure 2A). In patient DGP, who was not treated with
aggressive immunosuppression, anti-NPC titers remained elev-
ated over time.
Anti-NPC Autoantibody Is Found Only in Overlap
Myositis Sera
Anti-NPC were present in 4 (4%) patients of our cohort of
100 consecutive patients with AIM52 (Table 3). Anti-NPC were
not found in sera from 393 adult patients with systemic sclerosis
(n¼ 112), systemic lupus erythematosus (n¼ 94), rheumatoid
arthritis (n¼ 45) (these diseases defined according to ACR
criteria), MCTD (n¼ 35), autoimmune hepatitis (n¼ 13), psor-
iatic arthritis (n¼ 19), ankylosing spondylitis (n¼ 22), primary
gout (n¼ 33), or primary osteoarthritis (n¼ 20), nor were they
observed in sera from 62 normal adults. By 2-sided Fisher exact
test, the association of anti-NPC with AIM was highly signifi-
cant: for AIM versus all disease and normal controls, OR 42.4
(95%CI 2.3–796), p¼ 0.001; AIM vs disease controls only, OR
36.7 (95% CI 1.96–688), p¼ 0.0016.
The Predominant Anti-NPC Isotype is IgG
The anti-NPC isotype present in all 4 patients at myositis
diagnosis was IgG (see Table 2). In patients LGL and BP, only
IgG anti-NPC was present. Patient DGP also expressed strong
IgA anti-NPC, whereas patient AL expressed IgM as well as
IgA anti-NPC, albeit at lower intensity than IgG.
Lack of Other IgG Autoantibody Connective
Tissue Disease Marker in Anti-NPC Sera
No other IgG autoantibody marker for a defined connec-
tive tissue disease or to an overlap syndrome was identified in
anti-NPC positive sera (see Table 2). Specifically, autoanti-
bodies were absent to synthetases (Jo-1, PL-7, PL-12, OJ, EJ,
KS, Tyr, and Zo), SRP, systemic sclerosis-specific autoantigens
(CENP-B, topoisomerase I, RNA polymerase III, and Th/To),
and to autoantigens associated with MCTD and systemic
sclerosis or SLE in overlap (U1-U2-U3-U5RNP, PM-Scl, and
Ku). Anti-p155/140, anti-MDA5, and anti-MJ were also nega-
tive.
Other Autoantibodies
Anticardiolipin and lupus anticoagulant antibodies were
absent.
Heterogeneity of Nucleoporin Autoantigens
Nup358/RanBP2, a major component of the cytoplasmic
filaments of the NPC is the autoantigen reactive with anti-NPC
from patients DGP and AL (unpublished data and refer-
ences53,54) (see Table 2). In addition, DGP serum reacted with
gp210 but only by LIA. By immunoblotting, DGP serum did not
react at all with gp210 and by immunogold electron micro-
scopy, the NPC localization was typical of Nup358/RanBP2 and
not that of gp210.53,54
Anti-Nup SyndromeLGL serum was previously shown to react by immuno-
blotting with polypeptides of 200 kD and 130 kD enriched in
nuclear envelopes.10 In addition, LGL serum reacted by ALBIA
www.md-journal.com | 389
TABLE 2. Immunological profiles of 4 patients with autoantibodies to nuclear pore complexes (NPC) at myositis diagnosis
PATIENTS LGL DGP BP AL
Serum number 2839, 2841 2918, 2961 6373, 7217 9544,10064 13738
Anti-NPC titer

1:1,280 1:2,560 1:2,560 1:10,240
Anti-NPC isotypes

IgG þþþ þþþ þþþ þþþ
IgM    þþ
IgA  þþþ  þ
Specificities associated with anti-NPC sera
Nup358/RanBP2 (20,21)  þ  þ
gp210  þ  
Nup90 (22,23)   þ 
p200/p130 (11) þ   
Nup62 þ   
Myositis, overlap and CTD autoantibodies
Anti-synthetases    
Anti-U1,-U2,-U3,-U5RNP    
Anti-PM-Scl    
Anti-Ku-72, -Ku-86    
Anti-MDA5    
Anti-p155/140, -MJ    
Anti-Ku-72, -Ku-86    
Anti-fibrillarin    
Anti-Ro, -Ro52/TRIM21, -La    
Anti-CENP-B, -Th/To    
Anti-topoisomerase I    
Anti-RNA polymerase III    
Anti-nDNA, Sm    
Anti-phospholipidy    
RA autoantibodiesz
Anti-CCP, Units  þ, 147.2 þ, 168.9 þ, 26.9
Rheumatoid factor, kU/L  þ, 73 þ, 3090 þ, 283
Autoimmune liver disease autoantibodies
AMA-M2  þ  
AMA-M2-3E(BPO)    
Sp100    
PML    
LKM-1    
LC-1    
SLA/LP    
Anti-mitochodrial    
Anti-smooth muscle    

By indirect immunofluorescence on HEp-2 cells.
0 U
Sene´cal et al Medicine  Volume 93, Number 24, November 2014with Nup62. Last, patient BP anti-NPC serum at a dilution of
1:500 reacted by immunoblotting with a single band of 90 kD
protein in HeLa cells, rat cells and in Xenopus laevis and
Pleurodele oocyte nuclear envelopes.9,27 By immunoelectron
microscopy, anti-NPC from patient BP reacted with intranuc-
lear filaments attached to NPCs. Taken together, these features
suggested that patient BP serum recognized a novel nup, nup90,
distinct from central domain-localized nup95 and intranuclear
filament-associated nup153, as previously reported.9,27
Given that autoantibodies to gp210 and nup p62 have been
associated with PBC, sera from the 4 patients were also tested
for reactivity against a panel of autoantigens associated with
autoimmune liver disease (see Table 2). All sera were negative
yLupus anticoagulant, IgG and IgM anticardiolipin antibodies.
zNormal serum values: rheumatoid factor < 45 kU/L, anti-CCP < 2except for DGP serum, which was positive for anti-mitochon-
drial M2 antibodies, but not for anti-M2–3E(BPO). Of interest,
all patient sera were negative for antimitochondrial and anti-
390 | www.md-journal.comsmooth muscle antibodies by indirect immunofluorescence on
mouse tissues and for mitochondrial fluorescence on HEp-2
cells. Because of mildly elevated serum transaminases, and
before detection of raised serum CK and the subsequent diag-
nosis of myositis, patient LGL had a liver biopsy, which was
normal (see Table 1). Neither patient LGL nor patient DGP have
shown any clinical or enzymatic evidence of liver disease over
26 years and 23 years of follow-up, respectively. In patient
LGL, an abdominal ultrasound done 26 years after myositis
diagnosis because of longstanding MTX therapy revealed no
evidence of liver disease.
HLA Genotyping
.By PCR-SSOP, the DQA10501 allele was shared by all
4 patients (100%) with anti-nup (Table 4). The DPA10103
allele was also shared by all patients. Three of the patients also
# 2014 Lippincott Williams & Wilkins
TABLE 3. Frequency of autoantibodies to nuclear pore com-
plexes in 493 adults with autoimmune and non autoimmune
rheumatic diseases and 62 normal adults

Patients
n
Anti-NPC
positive, n (%)
Autoimmune myositisy 100 4z (4)
Mixed connective tissue disease 35 0 (0)
Systemic lupus erythematous 94 0 (0)
Rheumatoid arthritis 45 0 (0)
Systemic sclerosis 112 0 (0)
Autoimmune hepatitis 13 0 (0)
Psoriatic arthritis 19 0 (0)
Ankylosing spondylitis 22 0 (0)
Primary gout 33 0 (0)
Primary osteoarthritis 20 0 (0)
Normal subjects 62 0 (0)

Patients were screened at diagnosis for anti-NPC by indirect
immunofluorescence on HEp-2 cells as described in Methods.
yOverlap myositis, n¼ 68; polymyositis, n¼ 9; dermatomyositis,
n¼ 19; cancer-associated myositis, n¼ 4.The 4 index sera were from
the overlap myositis group.
zBy two-sided Fisher’s exact test, autoimmune myositis versus all
Medicine  Volume 93, Number 24, November 2014carried the DRb30101 allele. The DRB10301 allele was
identified in 2 patients.
DISCUSSION
To our knowledge, this is the first report describing the
association between anti-NPC autoantibodies and an overlap
syndrome with prominent myositis in a patient population of
connective tissue diseases sharing a common ethnogeographic
background. This clinical subset accounts for 4% of our cohort
of French Canadian patients with AIM.50 Subsetting of patients
with AIM according to their autoantibody markers is increas-
ingly used by clinicians to diagnose more accurately these
diseases, individualize their treatment and determine their
prognosis.12,22,49 Thus, the shared phenotypic, immunogenetic
and ethnogeographic characteristics in our patients with anti-
NPC raise the question whether a novel AIM-overlap subset, the
‘‘anti-nup syndrome,’’ may be recognized by the presence of
these autoantibodies.
Several data strongly support the concept of an ‘‘anti-nup
syndrome’’ (Table 5). First, patients with a high titer of IgG
disease and normal controls: OR 42.4 (95% CI 2.3–796), P¼ 0.001;
autoimmune myositis versus disease controls only: OR 36.7 (95% CI
1.96–688), P¼ 0.0016.anti-NPC autoantibodies share a similar clinical overlap syn-
drome. The 4 patients have in common prominent myositis as
well as rheumatoid factor positive, anti-CCP positive and
TABLE 4. MHC class II genotyping in 4 patients with autoantibo
MHC
PATIENTS HLA-DRb1

HLA-DRb3

LGL 1303/1601 0101
AL 0301/1601 0101
DGP 0301/1302 0101/0301
BP 1101 0202
# 2014 Lippincott Williams & Wilkinserosive rheumatoid arthritis, Raynaud phenomenon, mild inter-
stitial lung disease and trigeminal neuralgia (see Table 5). The
myositis features fulfilled proposed criteria for overlap myosi-
tis.50 At follow-up, no SLEmanifestations or cutaneous features
of dermatomyositis or systemic sclerosis were noted. Long-term
survival was excellent and the overall prognosis was good.
Second, the immunologic marker shared by these patients,
that is, anti-NPC, appears selectively expressed, that is, no other
myositis specific autoantibody, such as antisynthetases, nor any
marker autoantibody associated with overlap myositis, such as
anti-U1RNP, anti-U3RNP, anti-Ku, or anti-PM-Scl was ident-
ified.22,50 In fact, no other IgG autoantibody marker for a
connective tissue disease was detected other than anti-NPC.
Third, all 4 patients shared the MHC Class II allele
DQA10501, the frequency of which is increased in white
patients with AIM, most strikingly those with myositis specific
autoantibodies.1,34,42 Two of the patients also carried a linked
allele, DRB10301. These unexpected findings suggest that
patients with anti-NPC share immunogenetic disease suscepti-
bility and, moreover, that shared and specific immunopatho-
genic mechanisms of disease are involved in these patients.
Overall, the shared DQA10501 allele brings strong pathophy-
siologic support to the concept of an ‘‘anti-nup syndrome.’’
Fourth, anti-NPC titers varied strikingly in parallel with
myositis activity, suggesting a mechanistic relationship, as yet
undefined, to the pathophysiology of the disease. Interestingly,
a similar fluctuation with myositis activity has been observed
with anti-Jo-1 autoantibodies, which are markers for another
overlap myositis syndrome, the antisynthetase syndrome.29
Last, the molecular heterogeneity of nup autoantigens is
reminiscent of the antigenic heterogeneity observed in the
antisynthetase syndrome, where autoantibodies to 8 synthetase
autoantigens have been identified.46,49 None of the 4 patients
with anti-nup displayed an antisynthetase. Moreover, there are
major clinical differences between the clinical features in our
patients and antisynthetase syndrome manifestations, including
in the latter more severe interstitial lung disease, fever, derma-
tomyositis cutaneous features and a poorer prognosis with
decreased survival.52 Thus, taken altogether, the data are con-
sistent with an apparent ‘‘anti-nup syndrome’’ in our patient
population.
This is the first report on anti-NPC autoantibodies encom-
passing a large group of patients from a uniform ethnogeo-
graphic background and with well-defined connective tissue
diseases who were systematically screened by indirect immu-
nofluorescence for the characteristic NPC fluorescent ANA
pattern. Other reports are mostly case reports and have major
methodologic differences with the present study, including
absence of controls and lack of long-term follow-up. Anti-
Anti-Nup SyndromeNPC were reported in 10 patients with connective tissue dis-
eases from various ethnogeographic backgrounds.11,25,26,30
Anti-gp210 was noted in 2 patients with rheumatoid arthritis
dies to nuclear pore complexes
CLASS II GENOTYPING
HLA-DQb1

HLA-DQA1

HLA-DPA1

0301/0502 0102/0501 0103
0201/0502 0102/0501 0103
0201/0604 0102/0501 0103/0201
0301 0501 0103/0201
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TABLE 5. Summary of "anti-nup syndrome" features
Clinical features Immunological features
Myositis, usually refractory to corticosteroids, chronic and relapsing
but remitting with addition of a second immunomodulating drug
Positive ANA in high titer with punctate nuclear envelope
(peripheral, rim) pattern
Rheumatoid arthritis, erosive, rheumatoid factor and anti-CCP
positive (may precede or follow myositis)
IgG dominant anti-NPC isotype
Raynaud phenomenon No other IgG autoantibody marker for connective tissue diseases
Trigeminal neuralgia Anti-NPC titers vary in parallel with myositis activity
Mild intertistial lung disease Heterogeneous and highly conserved nucleoporin autoantigens
Weight loss Shared MHC class II allele DQA10501
No SLE or cutaneous features of systemic sclerosis or
dermatomyositis
Antigen-driven immune response with features of pathogenic
autoantibodies
Absence of liver disease
Normal serial nailfold capillary microscopy
No cancer
Sene´cal et al Medicine  Volume 93, Number 24, November 2014and Sjo¨gren syndrome, respectively.25 Anti-p62 was reported in
4 patients with Sjo¨gren syndrome,30 2 patients with rheumatoid
arthritis,30 and a single MCTD patient with myositis requiring
immunosuppressive treatment.26 Last, autoantibodies to
Nup153 were reported in a single SLE patient.11 The few
controlled studies are cross-sectional and focused on PBC
and reactivity with a single nup. For example, in a French
study of anti-gp210, 25% (n¼ 72) of 285 patients with PBC
expressed the antibody whereas of 116 control patients with
SLE, seropositive rheumatoid arthritis or systemic vasculitis, a
single patient was positive for anti-gp210, for whom follow-up
was not available.3
In summary, the relationship, if any, between these reports
and the present study cannot be ascertained given methodologic
differences, including lack of well-defined and large connective
tissue disease control groups, testing restricted to reactivity with
a single nup, lack of clinical phenotype description and/or
absence of long-term follow-up. In addition, none of these
patients was evaluated specifically for the anti-Nup358/
RANBP2, anti-p90, or anti-p200/p130 specificities observed
in the present study. Therefore, it will be important to study the
frequency of anti-NPC as well as the associated phenotypes,
antigenic specificities and immunologic features in other large
international series of patients with connective tissue diseases,
and particularly among patients with an overlap myositis syn-
drome.
Several nup specificities were identified by sera from our
patients, indicating that the nup autoantigens are heterogeneous.
Polypeptides of 200 kd and 130 kd were detected by LGL serum
on immunoblots of nuclear envelope preparations.10 LGL
serum also reacted with Nup62 by ALBIA.31,42 Nup358/
RANBP2 was recognized by 2 patient sera (DGP and AL).
A 180 kd polypeptide was initially identified as the autoantigen
targeted by DGP serum and was called Nup180.53 Later,
Nup180 was identified as a Nup358/RanBP2 fragment.54
Nup358/RanBP2 is a major component of the NPC cytoplasmic
filaments and is essential for nuclear transport, mitosis and cell
viability.16,54 In the search for the antigenic specificities associ-
ated with anti-NPC in our patients, we screened their sera for
anti-gp210 and anti-Nup62. Interestingly, DGP serum (but not
Good prognosis with excellent long-term survivalAL serum) reacted with gp210. However, by immunoblotting
DGP serum did not react at all with gp210 and by immunogold
electron microscopy, the NPC localization of Nup358/RanBP2
392 | www.md-journal.comwas distinct from gp210.53,54 Taken altogether, these data
suggest that cross-reactive epitopes may account for the reac-
tivity of DGP serum with gp210. Indeed, partial amino acid
sequence homology was identified between Nup358/RanBP2
and gp210. For example, the Nup358/RanBP2 LLLK and
SELAAL sequences are similar, respectively, to the gp210
LELK and STLAGL sequences.
The present report expands to the nuclear envelope, and
specifically to the NPCs, the cellular compartments where
autoantigens associated with overlap myositis syndromes are
localized. Thus far, this had been restricted to the nucleus and to
the cytoplasm. Autoantibodies to the nuclear autoantigens
U1RNP, U3RNP, Ku and PM-Scl are associated with various
overlap myositis syndromes. In contrast, autoantibodies to the
cytoplasmically localized synthetases and MDA5 autoantigens
are associated, respectively, with the antisynthetase syndrome
and with a dermatomyositis overlap syndrome. The latter
syndromes are phenotypically distinct from the former ANA-
associated syndromes and, in turn, appear distinct from anti-nup
syndrome features,15,49 although a larger number of patients
with connective tissue diseases and anti-nup autoantibodies will
need to be studied.
The autoantigens identified by our patient sera are also
intriguing in light of the differential localization of these
proteins within the NPC structure. Nup358/RanBP2 is found
at the cytoplasmic face of the NPC while gp210 is part of the
central framework.18a,27 Nup62 is a complex of proteins (p62,
p60, and p54) also localized in the central framework compos-
ing the central channel.18a,21 In contrast, Nup90, identified
using anti-NPC serum from patient BP, localizes at the intra-
nuclear NPC-attached filaments.27 The exact relationship
between the molecular identity and cellular localization of these
autoantigens and the corresponding overlap myositis syndromes
remains to be deciphered.
Several features of the autoimmune response that charac-
terizes anti-NPC autoantibodies in our patients deserve com-
ment (see Table 5). Anti-NPC were predominantly of IgG
isotype and present in high titers at diagnosis. Anti-NPC varied
in parallel with myositis activity or persisted in high titers over
time and were directed to highly conserved antigenic determi-
nants within the cytoplasmic, nuclear or central framework of
the NPC. Taken together, these features suggest that nup
autoantigens themselves drive the anti-nup autoimmune
# 2014 Lippincott Williams & Wilkins
response. The absence of other connective tissue disease marker
autoantibodies is consistent with antigen selectivity and a highly
focused immune response. Thus, anti-nup autoantibodies
appear antigen-driven and display some features of pathogenic
autoantibodies.32
The initiating event that trigger anti-nup immune responses
is unknown. In PBC, molecular mimicry following hepatitis B
virus infection was evoked as a potential mechanism, as certain
nup aminoacid sequencesdisplay similaritywithhepatitisBvirus
DNApolymerase.13However, PBCpatient sera did not reactwith
the shared epitopes.13 None of our 4 patients with anti-NPC had
serologic evidence of hepatitis B virus infection. Mimicry of
bacterial antigenic determinants has also been proposed since the
predominant autoepitope of gp210 recognized by anti-gp210
from 25 PBC patients is homologous to Escherichia coli mut
Y and Salmonella typhimuriummut B gene products.33 However,
further study revealed that mut Y gene product was not recog-
nized by anti-gp210 autoantibodies.8
Finally, although no direct mechanistic link between anti-
NPC and myositis is established, a specific pathophysiologic
link between nups and striated skeletal muscle is suggested by
the correlation between anti-NPC titers and myositis activity.
Interestingly, other nuclear envelope components are known
to be critical in muscle disease. For example, emerin and lamin
A/C gene mutations are associated with specific muscular
dystrophies.7,44 Furthermore, Asally et al2 have identified a
key role for Nup358 in skeletal myogenesis. More studies are
needed to clarify the pathophysiologic link between anti-nup
autoantibodies and the ‘‘anti-nup syndrome.’’
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